Loading clinical trials...
Loading clinical trials...
This study is designed to evaluate the efficacy of icotinib as adjuvant therapy in treating such patients. The primary endpoint is to compare the recurrence-free survival after 1-year or 2-year treatm...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Betta Pharmaceuticals Co., Ltd.
NCT04895709 · Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, and more
NCT07336732 · Non-Small-Cell Lung Cancer
NCT06693336 · Carcinoma, Non-Small-Cell Lung Cancer (NSCLC)
NCT06747585 · Squamous Non-small-cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, and more
NCT05568212 · Non-small-cell Lung Cancer Patients
Beijing Cancer hospital
Beijing
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions